OTX2 activity at distal regulatory elements shapes the chromatin landscape of group 3 medulloblastoma

Cancer Discovery

Volumn 7, Issue 3, 2017, Pages 288-301

  Boulay, Gaylor ^a,b   Awad, Mary E ^a   Riggi, Nicolo ^c   Archer, Tenley C ^b,d   Iyer, Sowmya ^a   Boonseng, Wannaporn E ^a   Rossetti, Nikki E ^a   Naigles, Beverly ^a   Rengarajan, Shruthi ^a   Volorio, Angela ^a,c   Kim, James C ^a   Mesirov, Jill P ^b,e   Tamayo, Pablo ^b,e   Pomeroy, Scott L ^b,d   Aryee, Martin J ^a,b   Rivera, Miguel N ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; BRM PROTEIN; DNA; E1A ASSOCIATED P300 PROTEIN; HISTONE H3; NEUROGENIC DIFFERENTIATION FACTOR; NIMA RELATED KINASE; NIMA RELATED KINASE 2; PROTEIN; RNA; TRANSCRIPTION FACTOR OTX2; TUBBY RELATED PROTEIN 1; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; NEK2 PROTEIN, HUMAN; NEUROD1 PROTEIN, HUMAN; OTX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR OTX;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENHANCER REGION; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; GENOME-WIDE ASSOCIATION STUDY; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; LENTIVIRUS INFECTION; MEDULLOBLASTOMA; MESENCHYMAL STEM CELL; MITOSIS; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CEREBELLUM TUMOR; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL SURVIVAL; CEREBELLAR NEOPLASMS; CHROMATIN; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDULLOBLASTOMA; MESENCHYMAL STROMAL CELLS; NIMA-RELATED KINASES; OTX TRANSCRIPTION FACTORS;

EID: 85014736775     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0844     Document Type: Article

References (56)

1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015; 17 (Suppl 4): iv1-iv62.
2. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006; 24: 1924-31.
3. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008; 3: e3088.
4. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29: 1424-30.
5. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29: 1408-14.
6. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol 2012; 123: 465-72.
7. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012; 123: 473-84.
8. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488: 106-10.
9. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012; 488: 49-56.
10. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488: 43-8.
11. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488: 100-5.
12. G ibson P, T ong Y, R obinson G, T hompson M C, C urrle D S, E den C, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010; 468: 1095-9.
13. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76.
14. Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003; 4: 361-70.
15. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005; 121: 465-77.
16. Suva ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 2014; 157: 580-94.
17. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013; 339: 1567-70.
18. Leung D, Jung I, Rajagopal N, Schmitt A, Selvaraj S, Lee AY, et al. Integrative analysis of haplotype-resolved epigenomes across human tissues. Nature 2015; 518: 350-4.
19. Tsankov AM, Gu H, Akopian V, Ziller MJ, Donaghey J, Amit I, et al. Transcription factor binding dynamics during human ES cell differentiation. Nature 2015; 518: 344-9.
20. Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al. Integrative analysis of 111 reference human epigenomes. Nature 2015; 518: 317-30.
21. Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, et al. An atlas of active enhancers across human cell types and tissues. Nature 2014; 507: 455-61.
22. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57-74.
23. Lin CY, Erkek S, Tong Y, Yin L, Federation AJ, Zapatka M, et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature 2016; 530: 57-62.
24. Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 2005; 65: 919-24.
25. Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan C G, et al. OTX2 is critical for the maintenance and progression of Shhindependent medulloblastomas. Cancer Res 2010; 70: 181-91.
26. Bunt J, Hasselt NE, Zwijnenburg DA, Hamdi M, Koster J, Versteeg R, et al. OTX2 directly activates cell cycle genes and inhibits differentiation in medulloblastoma cells. Int J Cancer 2012; 131: E21-32.
27. Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, et al. Medulloblastomics: The end of the beginning. Nat Rev Cancer 2012; 12: 818-34.
28. Weeraratne SD, Amani V, Teider N, Pierre-Francois J, Winter D, Kye MJ, et al. Pleiotropic effects of miR-183∼96∼182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol 2012; 123: 539-52.
29. Beby F, Lamonerie T. The homeobox gene Otx2 in development and disease. Exp Eye Res 2013; 111: 9-16.
30. Buecker C, Srinivasan R, Wu Z, Calo E, Acampora D, Faial T, et al. Reorganization of enhancer patterns in transition from naive to primed pluripotency. Cell Stem Cell 2014; 14: 838-53.
31. Yang SH, Kalkan T, Morissroe C, Marks H, Stunnenberg H, Smith A, et al. Otx2 and Oct4 drive early enhancer activation during embryonic stem cell transition from naive pluripotency. Cell Rep 2014; 7: 1968-81.
32. Boon K, Eberhart CG, Riggins GJ. Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res 2005; 65: 703-7.
33. Hovestadt V, Jones DT, Picelli S, Wang W, Kool M, Northcott PA, et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 2014; 510: 537-41.
34. Rostomily RC, Bermingham-McDonogh O, Berger MS, Tapscott SJ, Reh TA, Olson JM. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res 1997; 57: 3526-31.
35. Bai RY, Staedtke V, Lidov HG, Eberhart CG, Riggins GJ. OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells. Cancer Res 2012; 72: 5988-6001.
36. Bunt J, Hasselt NA, Zwijnenburg DA, Koster J, Versteeg R, Kool M. OTX2 sustains a bivalent-like state of OTX2-bound promoters in medulloblastoma by maintaining their H3K27me3 levels. Acta Neuropathol 2013; 125: 385-94.
37. Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, Cristiano B, et al. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer 2014; 13: 72.
38. Xia J, Franqui Machin R, Gu Z, Zhan F. Role of NEK2A in human cancer and its therapeutic potentials. Biomed Res Int 2015; 2015: 862461.
39. Cowley GS, Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data 2014; 1: 140035.
40. Henise JC, Taunton J. Irreversible Nek2 kinase inhibitors with cellular activity. J Med Chem 2011; 54: 4133-46.
41. Frantz GD, Weimann JM, Levin ME, McConnell SK. Otx1 and Otx2 define layers and regions in developing cerebral cortex and cerebellum. J Neurosci 1994; 14: 5725-40.
42. Miyata T, Maeda T, Lee JE. NeuroD is required for differentiation of the granule cells in the cerebellum and hippocampus. Genes Dev 1999; 13: 1647-52.
43. Vernay B, Koch M, Vaccarino F, Briscoe J, Simeone A, Kageyama R, et al. Otx2 regulates subtype specification and neurogenesis in the midbrain. J Neurosci 2005; 25: 4856-67.
44. Pataskar A, Jung J, Smialowski P, Noack F, Calegari F, Straub T, et al. NeuroD1 reprograms chromatin and transcription factor landscapes to induce the neuronal program. EMBO J 2016; 35: 24-45.
45. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, Baumer K, et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev 2010; 24: 916-32.
46. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS, et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 2008; 4: e1000242.
47. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007; 448: 553-60.
48. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-60.
49. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24-6.
50. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): High-performance genomics data visualization and exploration. Brief Bioinform 2013; 14: 178-92.
51. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008; 9: R137.
52. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, et al. Software for computing and annotating genomic ranges. PLoS Comput Biol 2013; 9: e1003118.
53. Pohl A, Beato M. bwtool: A tool for bigWig files. Bioinformatics 2014; 30: 1618-9.
54. Tan G, Lenhard B. TFBSTools: An R/bioconductor package for transcription factor binding site analysis. Bioinformatics 2016; 32: 1555-6.
55. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 2010; 38: 576-89.
56. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods 2013; 10: 1213-8.